Replies to post #521602 on NorthWest Biotherapeutics Inc (NWBO)

[HyGro]

Primary endpoints are what get's approval. That's why investors aren't enthused by NWBO tossing out their original primary endpoint.

Here's the Novocure press release on the nGBM results:
"The five-year survival rate increased from five percent to 13 percent for patients treated with Optune together with temozolomide versus patients treated with temozolomide alone. These are the best results reported for newly diagnosed GBM patients in a phase 3 trial to date and represent a new landmark for five-year survival rate in this difficult to treat disease."

JAMA is a closed site, so here's the press release on the highlights:
https://www.novocure.com/jama-publishes-final-analysis-of-ef-14-phase-3-pivotal-trial-of-optune-together-with-temozolomide-demonstrating-unprecedented-survival-results-for-newly-diagnosed-glioblastoma/